Last reviewed · How we verify
NCT06865144
Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT
Phase 4 trial testing Netarsudil ophthalmic solution 0.02% in Primary Open Angle Glaucoma or Ocular Hypertension in 70 participants. Currently enrolling.
1 April 2026
Quick facts
| Lead sponsor | East Coast Institute for Research |
|---|---|
| Phase | Phase 4 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 70 |
| Start date | 27 June 2025 |
| Primary completion | 1 April 2026 |
| Estimated completion | 1 April 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Netarsudil ophthalmic solution 0.02% — full drug profile →
- Artificial tears — full drug profile →
Conditions studied
- Primary Open Angle Glaucoma or Ocular Hypertension — all drugs for Primary Open Angle Glaucoma or Ocular Hypertension →
Sponsor
East Coast Institute for Research
Who can join
18 and older, any sex, with Primary Open Angle Glaucoma or Ocular Hypertension. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to collect data about how Rhopressa affects IOP in patients who have had an SLT procedure in both eyes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06865144
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Netarsudil ophthalmic solution 0.02%
Trials testing the same drug.
- NCT04620135 — Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophth · Phase 3 · completed
Other recruiting trials for Primary Open Angle Glaucoma or Ocular Hypertension
Currently open trials in the same condition.
- NCT07076303 — A Prospective Study on the Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in Achieving >20% Intraocular Press · recruiting
Other East Coast Institute for Research trials
Trials by the same sponsor.
- NCT06987201 — Effects of DigiVibe on Pain in Subjects Undergoing Intramuscular Injections, Subcutaneous Injections, and Fingersticks · NA · completed
- NCT05827133 — Effect of Intraocular Lens (IOL) Centration and Tilt on Visual Performance With Clareon® Vivity® IOL Implantation · completed
- NCT03495908 — Regular Insulin vs Rapid Insulin Delivered by V-Go · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06865144 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by East Coast Institute for Research
- Last refreshed: 2 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06865144.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing